Premier Announces Letter of Intent With Siemens Financial China


VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 26, 2013) -

NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

Premier Diagnostic Health Services Inc. ("PDH") (CNSX:PDH) is pleased to announce that it has entered into a Letter of Intent (LOI) with Siemens Finance and Leasing Ltd. (SFLL) in Beijing, PRC to provide Premier with Vendor/lease financing for the purchase of advanced MRI and PET/CT medical imaging equipment for the Company's planned Centres for Advanced Diagnostics in China.

PDH is currently planning to develop and operate 35 Centres for Advanced Diagnostics in which high end diagnostic imaging equipment will be acquired, installed and operated. The capital cost of diagnostic equipment for each of the planned centres is projected to exceed CDN$2,000,000.The financing will be available for the acquisition of Siemens equipment and may be extended to the purchase/lease of non Siemens equipment.

"Premier and Siemens have a history of cooperation, and this mutually beneficial financial arrangement means that Premier can expeditiously move forward with its goal of multiple imaging centres throughout China," said Denis Tusar, Premier President and CEO.

About Premier Diagnostic Health Services Inc. ("PDH")

PDH is a Canadian company that provides advanced medical diagnostic tools utilizing of PET/CT Technology and/or MRI Technology and related diagnostic skills in Canada and, in partnership with hospitals and clinics in the People's Republic of China. The company's vision is to provide services and that support "improving medical decisions" around the world. The company's approach involves building long-term relationships covering management, quality, and financial services that are necessary to build, operate, and grow hospitals' and Clinics' diagnostic capacity and capability.

Except for historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Premier. (Not for dissemination in the United States of America).

The Canadian National Stock Exchange has neither approved nor disapproved the contents of this press release.

Contact Information:

Premier Diagnostic Health Services Inc.
Daniel Waters
Investor Relations
(604) 678.9120 Ext. 236
(604) 678.9278 (FAX)
dwaters@premierdiagnostics.ca
www.premierdiagnostics.ca

For Investment Purposes Contact:
Premier Diagnostic Health Services Inc.
Aggie Klepl
(604) 678.9120 Ext. 232
(604) 678.9278 (FAX)
aggiek@hotmail.com
www.premierdiagnostics.ca